English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Thy‐1 restricts steatosis and liver fibrosis in steatotic liver disease (advance online)

Blank, V., Karlas, T., Anderegg, U., Wiegand, J., Arnold, J., Bundalian, L., et al. (2024). Thy‐1 restricts steatosis and liver fibrosis in steatotic liver disease (advance online). Liver International. doi:10.1111/liv.15956.

Item is

Files

show Files
hide Files
:
Blank_Thy-1_LivInt_2024.pdf (Publisher version), 4MB
Name:
Blank_Thy-1_LivInt_2024.pdf
Description:
-
OA-Status:
Hybrid
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
2024
Copyright Info:
-

Locators

show

Creators

show
hide
 Creators:
Blank, Valentin, Author
Karlas, Thomas, Author
Anderegg, Ulf, Author
Wiegand, Johannes, Author
Arnold, Josi, Author
Bundalian, Linnaeus, Author
Le Duc, Gabriela-Diana1, Author                 
Körner, Christiane, Author
Ebert, Thomas, Author
Saalbach, Anja, Author
Affiliations:
1Department of Evolutionary Genetics, Max Planck Institute for Evolutionary Anthropology, Max Planck Society, ou_1497672              

Content

show
hide
Free keywords: metabolic dysfunction-associated; metabolic dysfunction-associated steatohepatitis; steatotic liver disease; steatotic liver disease fibrosis; Thy-1
 Abstract: Background and Aims: Steatotic liver disease (SLD) is generally considered to represent a hepatic manifestation of metabolic syndrome and includes a disease spectrum comprising isolated steatosis, metabolic dysfunction-associated steatohepatitis, liver fibrosis and ultimately cirrhosis. A better understanding of the detailed underlying pathogenic mechanisms of this transition is crucial for the design of new and efficient therapeutic interventions. Thymocyte differentiation antigen (Thy-1, also known as CD90) expression on fibroblasts controls central functions relevant to fibrogenesis, including proliferation, apoptosis, cytokine responsiveness, and myofibroblast differentiation. Methods: The impact of Thy-1 on the development of SLD and progression to fibrosis was investigated in high-fat diet (HFD)-induced SLD wild-type and Thy-1-deficient mice. In addition, the serum soluble Thy-1 (sThy-1) concentration was analysed in patients with metabolic dysfunction-associated SLD stratified according to steatosis, inflammation, or liver fibrosis using noninvasive markers. Results: We demonstrated that Thy-1 attenuates the development of fatty liver and the expression of profibrogenic genes in the livers of HFD-induced SLD mice. Mechanistically, Thy-1 directly inhibits the profibrotic activation of nonparenchymal liver cells. In addition, Thy-1 prevents palmitic acid-mediated amplification of the inflammatory response of myeloid cells, which might indirectly contribute to the pronounced development of liver fibrosis in Thy-1-deficient mice. Serum analysis of patients with metabolically associated steatotic liver disease syndrome revealed that sThy-1 expression is correlated with liver fibrosis status, as assessed by liver stiffness, the Fib4 score, and the NAFLD fibrosis score. Conclusion: Our data strongly suggest that Thy-1 may function as a fibrosis-protective factor in mouse and human SLD. © 2024 The Authors. Liver International published by John Wiley & Sons Ltd.

Details

show
hide
Language(s): eng - English
 Dates: 2024-05-04
 Publication Status: Published online
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Identifiers: DOI: 10.1111/liv.15956
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Liver International
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: - Sequence Number: - Start / End Page: - Identifier: ISSN: 1478-3223
ISSN: 1478-3231